We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy

LABORATORY


What sets us apart: the Molecular Oncology and Pathology Laboratory
The Pangaea Oncology laboratory, which serves IOR, is located in the Quirón Dexeus University Hospital, Barcelona. Its primary mission is to achieve personalized treatments according to the genetic characteristics of the disease, ensuring the quality, speed and accuracy of results so that therapy can be tailored to each patient.

Each tumor has its own genetic signature. The laboratory offers the possibility of specific molecular diagnosis, with the latest technology in the field of molecular biology, such as the determination of changes in the DNA sequence or the expression of critical genes in cancer using highly sensitive techniques such as PCR, real-time PCR and sequencing.

The laboratory team includes technical staff, biologists, pathologists and highly qualified and specialized investigators who combine experience in Molecular Diagnostics Services, pre-clinical oncology research, R+D Diagnostics, R+D Biomarker Discovery and Drug Development.
 

Pangaea Oncology is ENAC accredited for genetic analyses in tumor tissue and liquid biopsy samples
Pangaea was the first pharmacogenomics laboratory in Spain to be accredited by the National Accreditation Body (ENAC), ISO 15189, to perform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples (nº750 / LE15156 Annex 7). The laboratory is also accredited for analysis of EGFR mutations (exon 19, 20 (T790M) and 21), KRAS (exon 12-13) and BRAF (V600E) in tissue samples (see laboratory accreditation nº750 / LE15156 Annex 7).

Anexo Tec Rev 7 Alcance de la acreditación de 2016

 


Pangaea participates in the following Best Practice programs:

·         UK-NEQAS (EGFR, KRAS, BRAF, NRAS and EML4-ALK)

·         SEAP (Pathological Diagnosis and IHC)


The laboratory has also been positively audited by the Food and Drug Administration (FDA) as part of regulatory approval for Roche Diagnostics' Cobas® EGFR Mutation Test for non-small-cell lung cancer patients.